Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | HTR3A | P46098 | 5/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3539091 | 0.89 | HTR4 (0.61) | HTR4GAAHTR3ADRD2 | |
| SCHEMBL3544464 | 0.89 | HTR4 (0.61) | HTR4GAAHTR3ADRD2 | |
| SCHEMBL3549231 | 0.85 | HTR4 (0.52) | HTR4GAAHTR3A | |
| SCHEMBL3544454 | 0.83 | HTR7 (0.48) | HTR4HTR3AOPRK1MAPTDRD2 | |
| SCHEMBL3943811 | 0.81 | PIK3CA (0.46) | HTR4HTR3AOPRK1MAPTDRD2 | |
| SCHEMBL3543445 | 0.81 | PIK3CA (0.46) | HTR4HTR3AOPRK1MAPTDRD2 | |
| SCHEMBL3550487 | 0.77 | GAA (0.55) | HTR4GAAHTR3A | |
| SCHEMBL3543720 | 0.73 | MEN1 (0.55) | HTR3AOPRK1 | |
| SCHEMBL3543722 | 0.73 | MEN1 (0.55) | HTR3AOPRK1 | |
| SCHEMBL1780880 | 0.73 | MEN1 (0.55) | HTR3AOPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7709471-B2 | Compounds | ASTRAZENECA AB (SE) | 2010-05-04 | — | — | US | disclosed |
| US-20080009482-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009482-A1 | NOVEL COMPOUNDS | CYP11B2, CYP11B1, CYP46A1 | USP2 4608/4885HTR4 3043/4885GAA 159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.